ReportTwo randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris
Section snippets
Study design
Two 12-week, double-blind, randomized, parallel group, phase III studies were conducted under identical protocols to evaluate the efficacy and safety of dapsone gel, 5% (dapsone gel), compared with a vehicle gel control in the treatment of acne vulgaris. A total of 103 centers in the United States and Canada participated in the studies between November 2002 and September 2003.
Eligible patients were randomly assigned in a 1:1 ratio to either dapsone gel or vehicle gel according to a fixed-block
Patient disposition and baseline characteristics
A total of 3010 patients were enrolled and were dispensed dapsone gel (n = 1506) or vehicle gel (n = 1504) and made up the ITT population (Fig 1). The safety-evaluable population, defined as all enrolled subjects who applied study drug, included 1466 patients who received dapsone gel and 1467 who received vehicle gel. Approximately equal numbers from each treatment group discontinued treatment prematurely: 15.9% (240/1506) of the dapsone gel–treated patients and 17.5% (263/1504) of the vehicle
Discussion
These randomized, double-blind, vehicle-controlled studies show dapsone gel to be effective in the treatment of acne, as demonstrated by significantly greater success based on the investigator's GAAS and by the reduction of inflammatory, noninflammatory, and total lesion counts at the end of treatment. A significantly greater number of patients treated with dapsone gel than patients treated with vehicle gel had no acne or minimal acne on completion of treatment. Combined results from these two
References (20)
- et al.
Office-based physician services provided by dermatologists in the United States in 1990
J Invest Dermatol
(1994) The psychosocial impact of acne: patients' perceptions
J Am Acad Dermatol
(1995)- et al.
Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures
J Am Acad Dermatol
(2000) - et al.
Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin
J Am Acad Dermatol
(1987) - et al.
Epidemiology of headache in a general population—a prevalence study
J Clin Epidemiol
(1991) - et al.
Dapsone and sulfones in dermatology: overview and update
J Am Acad Dermatol
(2001) - et al.
Acne in schoolchildren: no longer a concern for dermatologists
BMJ
(1989) - et al.
The prevalence of common skin conditions in Australian school students: 3. Acne vulgaris
Br J Dermatol
(1998) - et al.
An epidemiological study of acne in female adults: results of a survey conducted in France
J Eur Acad Dermatol Venereol
(2001) - et al.
Acne vulgaris and the quality of life of adult dermatology patients
Arch Dermatol
(1998)
Cited by (130)
Acne treatment challenges – Recommendations of Latin American expert consensus
2024, Anais Brasileiros de DermatologiaPharmacologic management for polycystic ovary syndrome: Hirsutism and acne
2023, Polycystic Ovary Syndrome: Basic Science to Clinical Advances across the LifespanAcne vulgaris
2023, Encyclopedia of Child and Adolescent Health, First EditionTopical Antibacterial Agents
2020, Comprehensive Dermatologic Drug Therapy, Fourth EditionA review of diagnosis and treatment of acne in adult female patients
2018, International Journal of Women's DermatologyCitation Excerpt :Dapsone is a sulfone agent that is available in a 5% gel and used as a twice-daily agent or 7.5% gel used once daily. Data only show modest-to-moderate efficacy in the reduction of inflammatory acne lesions (Draelos et al., 2007; Lucky et al., 2007). Dapsone has a poorly understood mechanism in the treatment of patients with acne and its ability to kill P. acnes has been studied poorly (Zaenglein et al., 2016).
These studies were sponsored by QLT USA, Inc. and Astellas Pharma US, Inc.
Disclosure: Drs Draelos, Carter, Maloney, Elewski, Poulin, and Lynde were clinical investigators in the reported studies and received research support from the sponsoring companies. Dr Garrett is an employee of QLT USA, Inc.
These studies were presented in part at the 64th Annual Meeting of the American Academy of Dermatology, March 3-7, 2006, San Francisco, California.
- ∗
Additional members of the United States/Canada Dapsone Gel Study Group are available at www.eblue.org as an online-only appendix to this article.